Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: A retrospective analysis

Annals of Allergy, Asthma and Immunology

Volumn 111, Issue 1, 2013, Pages 51-55

  Shapiro, Ralph S ^a  

^a Midwest Immunology Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CHILD; CONTROLLED STUDY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; IMMUNOTHERAPY; INFANT; INFUSION PUMP; INFUSION RELATED REACTION; MALE; MEDICAL RECORD REVIEW; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; STEADY STATE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; INFUSION PUMPS; INFUSIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84879551412     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2013.04.015     Document Type: Article

References (23)

1. M. Berger, M. Rojavin, P. Kiessling, and O. Zenker Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies Clin Immunol 139 2011 133 141
2. M. Berger Subcutaneous administration of IgG Immunol Allergy Clin N Am 28 2008 779 802
3. A. Gardulf, U. Nicolay, and D. Math Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home J Allergy Clin Immunol 114 2004 936 942
4. U. Nicolay, P. Kiessling, and M. Berger Health-related quality fo life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home J Clin Immunol 26 2006 65 72
5. M. Berger, E. Murphy, P. Riley, G.E. Bergman VIRTUE Trial Investigators Improved quality of life, immunoglobulin G levels, and infection rate in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G South Med J 103 2010 856 863
6. J. Hoffmann, B. Grimbacher, J. Thiel, H.H. Peter, B.H. Belohradsky Vivaglobin Study Group Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency Eur J Med Res 15 2010 238 245
7. H.M. Chapel, G.P. Spickett, D. Ericson, W. Engl, M.M. Eibl, and J. Bjorkander The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy J Clin Immunol 20 2000 94 100
8. A. Gardulf, L. Hammarström, and C.I.E. Smith Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion Lancet 338 1991 162 166
9. H.D. Ochs, S. Gupta, P. Kiessling, U. Nicolay, M. Berger Subcutaneous IgG Study Group Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases J Clin Immunol 26 2006 265 273
10. A. Gardulf, U. Nicolay, and O. Asensio Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study J Clin Immunol 26 2006 177 185
11. E.D. Lobo, R.J. Hansen, and J. Balthasar Antibody pharmacokinetics and pharmacodynamics J Pharm Sci 93 2004 2645 2668
12. F.A. Bonilla Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes Immunol Allergy Clin N Am 28 2008 803 819
13. Vivaglobin, Immune Globulin Subcutaneous (Human) 16% Liquid Prescribing Information 2011 CSL Behring GmbH Marburg, Germany
14. Hizentra, Immune Globulin Subcutaneous (Human) 20% Liquid Prescribing Information 2011 CSL Behring AG CSL Behring LLC Bern, Switzerland
15. ®, the first 20% SCIG preparation: a practical approach Adv Ther 28 2011 521 533
16. R. Shapiro Subcutaneous immunoglobulin therapy by subcutaneous push is preferred to infusion by pump: a retrospective analysis J Clin Immunol 30 2010 301 307
17. F.A. Bonilla IgG replacement therapy, no size fits all Clin Immunol 139 2011 107 109
18. EMEA Committee for Proprietary Medicinal Products (CPMP. Note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use) 2002 European Agency for Evaluation of Medicinal Products London, England http://www.emea.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/10/WC500004255.pdf Accessed April 20, 2012
19. S. Jolles, E. Bernatowska, and J. de Gracia Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy Clin Immunol 141 2011 90 102
20. S.H. Desai, A. Chouksey, J. Poll, and M. Berger A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously J Allergy Clin Immunol 124 2009 854 856
21. Jolles S, Panahloo Z. Factors affecting infusion of high (20%) vs lower concentration (16%) SCIg in primary immunodeficiency disorders [abstract]. In: Proceedings from the Annual Meeting of the American Academy of Allergy Asthma & Immunology; March 2-6, 2012; Orlando, FL.
22. J.S. Orange, W.J. Grossman, R.J. Navickis, and M.M. Wilkes Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies Clin Immunol 137 2010 21 30
23. J.S. Orange, B.H. Belohradsky, and M. Berger Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy Clin Exp Immunol 169 2012 172 181